Concerning melanoma, preclinical studies testing epigenetic drugs, such as the hypomethylating agent 5-azacytidine and the pan-HDAC-i panobinostat, showed interesting antitumor effects [86,87]. This evidence concerns the gene HDAC9 and melanoma.